This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative colitis, while Skyrizi, a 3rd generation biologic, has gained share in Crohn’s Disease. Despite these newer entrants, 1st generation biologics maintain significant patient share in both diseases.
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...
1 in 4 people globally are already affected by NCDs. By 2030, NCDs will cause 55 million deaths per year under ‘business as usual.’1,2 Effective...
